These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 39199421)

  • 1. CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.
    Li W; Wang X; Zhang X; Aziz AUR; Wang D
    Biomolecules; 2024 Aug; 14(8):. PubMed ID: 39199421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of CAR-NK Cells Targeting cSCC-Specific Antigens for Precision Immunotherapy.
    Tayanloo-Beik A; Roudsari PP; Aghayan H; Arjmand R; Rezaei-Tavirani M; Larijani B; Rajaeinejad M; Mosaed R; Arjmand B
    Methods Mol Biol; 2024; 2849():253-263. PubMed ID: 38095836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
    Zhao Y; Zhou X
    Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.
    Peng L; Sferruzza G; Yang L; Zhou L; Chen S
    Cell Mol Immunol; 2024 Oct; 21(10):1089-1108. PubMed ID: 39134804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances and progress in immunotherapy of solid cancers.
    Kumar A; Emdad L; Das SK; Fisher PB
    Adv Cancer Res; 2024; 164():111-190. PubMed ID: 39306365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
    Andrea AE; Chiron A; Sarrabayrouse G; Bessoles S; Hacein-Bey-Abina S
    Front Immunol; 2024; 15():1459818. PubMed ID: 39430751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
    Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
    Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell-related anti-tumour adoptive cell immunotherapy.
    Qi Y; Li Y; Wang H; Wang A; Liu X; Liang Z; Gao Y; Wei L
    J Cell Mol Med; 2024 Jun; 28(11):e18362. PubMed ID: 38837666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.